The −675 4G/5G PAI-1 polymorphism confers genetic susceptibility to systemic lupus erythematosus, its clinical manifestations, and comorbidities in Mexican-Mestizo population

References

• Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2(1):16039.
   PubMedGoogle Scholar
• Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol. 2012;24(6):651–657.
   PubMed Web of Science ®Google Scholar
• Gualtierotti R, Biggioggero M, Penatti AE, et al. Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev. 2010;10(1):3–7.
   PubMed Web of Science ®Google Scholar
• Burgos PI, Alarcón GS. Thrombosis in systemic lupus erythematosus: risk and protection. Expert Rev Cardiovasc Ther. 2009;7(12):1541–1549.
   PubMedGoogle Scholar
• Dhillon PK, Adams MJ. Thrombosis in systemic lupus erythematosus: role of impaired fibrinolysis. Semin Thromb Hemost. 2013;39(04):434–440.
   PubMedGoogle Scholar
• Palatinus A, Adams M. Thrombosis in systemic lupus erythematosus. Semin Thromb Hemost. 2009;35(07):621–629.
   PubMedGoogle Scholar
• Kohler HP, Grant PJ. Plasminogen-Activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342(24):1792–1801.
   PubMed Web of Science ®Google Scholar
• Fortenberry YM. Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present). Expert Opin Ther Pat. 2013;23(7):801–15E.
   PubMed Web of Science ®Google Scholar
• Klinger KW, Winqvist R, Riccio A, et al. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA. 1987;84(23):8548–8552.
   PubMed Web of Science ®Google Scholar
• Ha H, Oh EY, Lee HB. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol. 2009;5(4):203–211.
   PubMed Web of Science ®Google Scholar
• Henry M, Chomiki N, Scarabin PY, Alessi MC, et al. Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol. 1997;17(5):851–858.
   PubMed Web of Science ®Google Scholar
• Eriksson P, Kallin B, van 't Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995;92(6):1851–1855.
   PubMed Web of Science ®Google Scholar
• Wong TY, Poon P, Szeto CC, et al. Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney Int. 2000;57(2):632–638.
   PubMed Web of Science ®Google Scholar
• Margaglione M, Cappucci G, Colaizzo D, et al. The PAI-1 Gene Locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol. 1998;18(2):152–156.
   PubMed Web of Science ®Google Scholar
• Vergouwen MD, Frijns CJ, Roos YB, et al. Plasminogen activator inhibitor-1 4G allele in the 4G/5G promoter polymorphism increases the occurrence of cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke. 2004;35(6):1280–1283.
   PubMed Web of Science ®Google Scholar
• Pooyan H, Ahmad E, Azadeh R. 4G/5G and A-844G polymorphisms of plasminogen activator Inhibitor- Associated with glioblastoma in Iran–a Case-Control study. Asian Pac J Cancer Prev. 2015;16(15):6327–6330.
   PubMedGoogle Scholar
• Luo Y, Wang C, Tu H. Impact of the 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene on primary nephrotic syndrome. Mol Med Rep. 2014;9(3):894–898.
   PubMed Web of Science ®Google Scholar
• De la Cruz-Mosso U, Muñoz-Valle JF, Salgado-Bernabé AB, et al. Body adiposity but not insulin resistance is associated with −675 4G/5G polymorphism in the PAI-1 gene in a sample of Mexican children. J Pediatr (Rio J). 2013;89(5):492–498.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang C, Chen N, et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis. Thromb Res. 2014;134(6):1241–1248.
   PubMed Web of Science ®Google Scholar
• Muñoz-Valle JF, Ruiz-Quezada SL, Oregón-Romero E, et al. PAI-1 mRNA expression and plasma level in rheumatoid arthritis: relationship with 4G/5G PAI-1 polymorphism. Rheumatol Int. 2012;32(12):3951–3956.
   PubMed Web of Science ®Google Scholar
• Padilla-Gutiérrez JR, Palafox-Sánchez CA, Valle Y, et al. Plasminogen activator inhibitor-1 polymorphisms (−844 G>A and HindIII C>G) in systemic lupus erythematosus: association with clinical variables. Clin Exp Med. 2011;11(1):11–17.
   PubMed Web of Science ®Google Scholar
• De la Cruz-Mosso U, Muñoz-Valle JF, Salgado-Goytia L, et al. Relationship of metabolic syndrome and its components with −844 G/A and HindIII C/G PAI-1 gene polymorphisms in Mexican children BMC Pediatr. BMC Pediatr. 2012;12:41.
   PubMed Web of Science ®Google Scholar
• De la Cruz-Mosso U, Elena Ramos-Arellano L, Francisco Muñoz-Valle J, et al. PAI-1 haplogenotype confers genetic susceptibility for obesity and hypertriglyceridemia in Mexican children. Invest Clin. 2016;57(3):246–258.
   PubMed Web of Science ®Google Scholar
• Szabó MZ, Szodoray P, Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunol Res. 2017;65(2):543–550.
   PubMed Web of Science ®Google Scholar
• Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res. 1988;16(3):1215.
   PubMed Web of Science ®Google Scholar
• Ruiz-Quezada S, Vázquez-Del Mercado M, Parra-Rojas I, et al. Genotype and allele frequency of PAI-1 promoter polymorphism in healthy subjects from the west of Mexico. Association with biochemical and hematological parameters. Ann Genet. 2004;47(2):155–162.
   PubMedGoogle Scholar
• Sullivan KM, Dean A, Soe MM. OpenEpi: A Web-based epidemiologic and statistical calculator for public health. Public Health Rep. 2009;124(3):471–474.
   PubMed Web of Science ®Google Scholar
• Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993;268(15):10739–10745.
   PubMed Web of Science ®Google Scholar
• Rangel-Villalobos H, Muñoz-Valle JF, González-Martín A, et al. Genetic admixture, relatedness, and structure patterns among Mexican populations revealed by the Y-Chromosome. Am J Phys Anthropol. 2008;135(4):448–461.
   PubMed Web of Science ®Google Scholar
• Fernandes KS, Sandrim VC. 4G/5G polymorphism modulates PAI-1 circulating levels in obese women. Mol Cell Biochem. 2012;364(1–2):299–301.
   PubMed Web of Science ®Google Scholar
• Hoffstedt J, Andersson IL, Persson L, et al. The common -675 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene is strongly associated with obesity. Diabetologia. 2002;45(4):584–587.
   PubMed Web of Science ®Google Scholar
• Solá E, Vayá A, España F, et al. Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism. Thromb Res. 2008;122(3):320–327.
   PubMed Web of Science ®Google Scholar
• Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb. 1993;13(12):1865–1873.
   PubMed Web of Science ®Google Scholar
• Moll S, Menoud PA, Fulpius T, et al. Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritis. Kidney Int. 1995;48(5):1459–1468.
   PubMed Web of Science ®Google Scholar
• Wang AYM, Poon P, Lai FM, et al. Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. Clin Neph. 2001;59:1520–1528.
   Google Scholar
• Gong R, Liu Z, Li L. Epistatic effect of plasminogen activator inhibitor 1 and beta-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis: interaction with environmental/clinical factors. Arthritis Rheum. 2007;56(5):1608–1617.
   PubMedGoogle Scholar
• Voulgarelis M, Kokori SI, Ioannidis JP, et al. Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin. Ann Rheum Dis. 2000;59(3):217–222.
   PubMed Web of Science ®Google Scholar
• Fayyaz A, Igoe A, Kurien BT, et al. Haematological manifestations of lupus. Lupus Sci Med. 2015;2(1):e000078.
   PubMed Web of Science ®Google Scholar
• Rhodes B, Fürnrohr BG, Vyse TJ. C-reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol. 2011;7(5):282–289.
   PubMed Web of Science ®Google Scholar
• Ozel Demiralp D, Aktas H, Akar N. The effect of plasminogen activator inhibitor-1 −675 4G/5G polymorphism on PAI-1 gene expression and adipocyte differentiation. Clin Appl Thromb Hemost. 2008;14(4):438–446.
   PubMed Web of Science ®Google Scholar